Endometriosis innovation earns Demetria The Trinity Bradfield Prize 2025
The hugely popular Trinity Bradfield Prize was awarded by Sir Greg Winter to endometriosis diagnosis start-up Demetria last week.
The finalists at The Bradfield Centre were culled from an astonishing variety of departments and colleges, with the winners assured of further exposure to mentors and investors.
Since starting in 2018, more than 450 teams have applied, £125,000 in non-dilutive prize money has been awarded, and alumni have gone on to raise millions of pounds in venture and grant funding.
Demetria founder Lorna MacLean collected the £10,000 first prize, with runners-up wins for Xufu Ren, of PowerMatrix, and Yizhou Yu, of Healthspan Biotics, who received £5,000 each.
Demetria is seeking to revolutionise endometriosis diagnosis by harnessing the power of AI and computer vision to guide and analyse ultrasound scans “because women and their clinicians deserve a better and faster method of diagnosing this disease”.
PowerMatrix, meanwhile, provides compact DC-DC power supplies for emerging and cutting-edge technologies including data centre and aerospace, while Healthspan Biotics (co-founded by Yizhou and Redgate Software co-founder Simon Galbraith) uses AI in the lab to identify how some individuals protect themselves against Alzheimer’s.
“It’s been another exceptional year for the prize, both in terms of quality and volume of applications,” said James Parton, managing director of The Bradfield Centre.
“I’ve been pleased with the reach of the competition across the University of Cambridge, with this year’s applications representing an impressive 34 departments and 24 colleges.”
“The quality bar was high, and the judges spent considerable time deliberating. I’m delighted for the teams winning the cash prizes, but all finalists will benefit from our ongoing support via mentoring, introductions and complimentary membership of The Bradfield Centre.”
James added: “It was also great to welcome back two of last year's winners - Ashraf Zarkan of BioTryp Therapeutics and Hendrik Runge of Cambridge Nucleomics.
“The impressive progress of both companies since winning the prize meant that the judges felt it was only fair to jointly award the Angel Prize - £5k each - for commercial progress over the past 12 months.
- Cambridge Tech Podcast interviews all the winners here.
